Anti-Human CD32 (FcγRIIA) [Clone IV.3] — Purified in vivo GOLD™ Functional Grade

Human K562 leukemia cell line

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

2-8°C wet ice

in vivo FcγRIIA blockade in humanized mice
in vitro FcγRIIA blockade
ELISA
Flow cytometry

Human FcγRII - binds most strongly to the RIIA isoform

The Anti-Human CD32 monoclonal antibody (Clone IV.3) specifically reacts with human CD32, a 40 kDa transmembrane glycoprotein expressed on monocytes, macrophages, B cells, and platelets. As an Fc receptor (FcγRIIA), CD32 mediates vital immune responses such as phagocytosis, ADCC, degranulation, and cytokine release by interacting with IgG-immune complexes. Clone IV.3 binds directly to the ligand-binding site, making it a powerful tool for blocking the functional effects of CD32 in vitro. Additionally, it is highly utilized in flow cytometry to eliminate non-specific background staining by effectively blocking Fc-receptors prior to antibody labeling.

Fc region of monomeric IgG (weakly), aggregated IgG (strongly)

P12318

1. Walsh TG, Harper MT, Poole AW. SDF-1α is a novel autocrine activator of platelets operating through its receptor CXCR4. Cell Signal. 2015 Jan;27(1):37-46. doi: 10.1016/j.cellsig.2014.09.021. Epub 2014 Oct 5. PMID: 25283599; PMCID: PMC4265729.
2. Ben Mkaddem S, Hayem G, Jönsson F, Rossato E, Boedec E, Boussetta T, El Benna J, Launay P, Goujon JM, Benhamou M, Bruhns P, Monteiro RC. Shifting FcγRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. J Clin Invest. 2014 Sep;124(9):3945-59. doi: 10.1172/JCI74572. Epub 2014 Jul 25. PMID: 25061875; PMCID: PMC4151227.
3. Flinsenberg TWH, Janssen WJ, Herczenik E, Boross P, Nederend M, Jongeneel LH, Scholman RC, Boelens JJ, Maas C, van Gijn ME, van Montfrans JM, Leusen JH, Boes M. A novel FcγRIIa Q27W gene variant is associated with common variable immune deficiency through defective FcγRIIa downstream signaling. Clin Immunol. 2014 Nov;155(1):108-117. doi: 10.1016/j.clim.2014.09.006. Epub 2014 Sep 19. PMID: 25242138.
4. Trist HM, Tan PS, Wines BD, Ramsland PA, Orlowski E, Stubbs J, Gardiner EE, Pietersz GA, Kent SJ, Stratov I, Burton DR, Hogarth PM. Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses. J Immunol. 2014 Jan 15;192(2):792-803. doi: 10.4049/jimmunol.1301554. Epub 2013 Dec 16. PMID: 24342805; PMCID: PMC4080885.